ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In a new contributed article, Hilde Vanaken explained how the traditional global-to-local model for translating trial materials fragments content through sequential adaptation, creating inefficiency and rework. A local-first approach using structured data and AI-orchestrated generation embeds stakeholder terminology and preferences from the start, reducing costs and timelines while improving clarity and relevance across countries and sites.
• In a recently released peer-reviewed study combining real-world data from CluePoints with Tufts CSDD benchmarks, researchers quantified financial impact of risk-based quality management in oncology trials, finding ROI multiples ranging from 6x to 23x. Phase duration reductions of 8-19% drove the largest value gains, reinforcing that proactive data-driven oversight extends beyond monitoring cost reduction to program-level time savings.
• FDA approved Merck's Lipfendra as the first oral PCSK9 inhibitor, offering patients a once-daily pill alternative to injectable therapies for LDL cholesterol lowering. CORALreef trials showed 56-60% reductions in LDL-C compared to placebo at week 24, with secondary reductions in non-HDL-C and apolipoprotein B, though cardiovascular outcomes data remains pending.

That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.